# Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

> **NCT06439225** · PHASE3 · RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 236 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06439225
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2029-09-30
- **Final completion:** 2030-03-31
- **Target enrollment:** 236 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06439225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06439225, "Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06439225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*